Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2026-04-17 Director's Dealing
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - SHAI LANKRY
Director's Dealing Classification · 90% confidence The document is an Israeli TASE/ISA announcement under Regulation 5 attaching a Form 3 filed with the SEC by Shai Lankry (a director reporting his beneficial ownership). This is an insider/Director’s dealing notification rather than a full report, earnings release, capital change, or AGM material. Therefore it fits the Director’s Dealing category (DIRS).
2026-04-17 English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - Gil Efron
Director's Dealing Classification · 90% confidence The document is a U.S. SEC Form 3 (Initial Statement of Beneficial Ownership of Securities) filed under Section 16(a) of the Exchange Act, reporting personal equity holdings and options by a company officer/director. This is an insider transaction report (director’s dealing).
2026-04-17 English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - Gil Efron
Director's Dealing Classification · 90% confidence The document is an Israeli securities filing under Regulation 5 notifying that the company has attached “Notification of a Form 3 filed with the SEC by Gil Efron.” A Form 3 is the initial insider beneficial-ownership statement submitted by directors/executives. This is a typical director’s dealing notice. Therefore it falls under the Director’s Dealing category.
2026-04-17 English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES -Agmon Ido
Director's Dealing Classification · 95% confidence The document is a U.S. SEC Form 3 (“Initial Statement of Beneficial Ownership of Securities”), filed under Section 16(a) by a company director reporting personal share ownership and stock options. This is an insider trading/beneficial ownership report by a director. Therefore it falls under the ‘Director’s Dealing’ category (Code: DIRS).
2026-04-17 English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES -Agmon Ido
Director's Dealing Classification · 75% confidence The document is an ISA/TASE Regulation 5 immediate report by Purple Biotech Ltd (a foreign private issuer), notifying the market that an SEC Form 3 was filed by an insider (Agmon Ido). A Form 3 is the initial beneficial ownership report for company insiders. This is not a full financial report but a director’s (insider’s) share holdings notification, fitting the “Director’s Dealing” category (insider transactions/holdings).
2026-04-17 English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES -Suzana Nahum-Zilberberg
Director's Dealing Classification · 96% confidence The document is SEC Form 3 “Initial Statement of Beneficial Ownership of Securities,” filed under Section 16(a) by a company director/officer reporting their personal holdings and derivative positions. This is an insider transaction/ownership report, matching the Director’s Dealing category.
2026-04-17 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.